191 related articles for article (PubMed ID: 25999236)
21. Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.
Ahmed AF; Samreen N; Grajo JR; Zendejas I; Sistrom CL; Collinsworth A; Esnakula A; Shah JL; Cabrera R; Geller BS; Toskich BB
Abdom Radiol (NY); 2018 Jul; 43(7):1825-1836. PubMed ID: 29052747
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
23. Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment.
Reiner CS; Gordic S; Puippe G; Morsbach F; Wurnig M; Schaefer N; Veit-Haibach P; Pfammatter T; Alkadhi H
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):400-8. PubMed ID: 26216725
[TBL] [Abstract][Full Text] [Related]
24. Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology.
Vietti Violi N; Gnerre J; Law A; Hectors S; Bane O; Doucette J; Abboud G; Kim E; Schwartz M; Fiel MI; Taouli B
Eur Radiol; 2022 Sep; 32(9):6493-6503. PubMed ID: 35380226
[TBL] [Abstract][Full Text] [Related]
25. Quantitative volumetric functional MR imaging: an imaging biomarker of early treatment response in hypo-vascular liver metastasis patients after yttrium-90 transarterial radioembolization.
Zhu X; Sobhani F; Xu C; Pan L; Ghasebeh MA; Kamel IR
Abdom Radiol (NY); 2016 Aug; 41(8):1495-504. PubMed ID: 26960726
[TBL] [Abstract][Full Text] [Related]
26. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization.
Lee JS; Lee HA; Jeon MY; Lim TS; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Han KH; Seo YS; Kim SU
Eur J Gastroenterol Hepatol; 2020 Jun; 32(6):739-747. PubMed ID: 31764406
[TBL] [Abstract][Full Text] [Related]
27. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes.
King MJ; Tong A; Dane B; Huang C; Zhan C; Shanbhogue K
Eur J Radiol; 2020 Dec; 133():109351. PubMed ID: 33096408
[TBL] [Abstract][Full Text] [Related]
28. Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases.
Seyal AR; Parekh K; Velichko YS; Salem R; Yaghmai V
Acad Radiol; 2014 Aug; 21(8):950-7. PubMed ID: 24833565
[TBL] [Abstract][Full Text] [Related]
29. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma.
Weng Z; Ertle J; Zheng S; Lauenstein T; Mueller S; Bockisch A; Gerken G; Yang D; Schlaak JF
Oncol Lett; 2013 Dec; 6(6):1707-1712. PubMed ID: 24260066
[TBL] [Abstract][Full Text] [Related]
30. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.
Vincenzi B; Di Maio M; Silletta M; D'Onofrio L; Spoto C; Piccirillo MC; Daniele G; Comito F; Maci E; Bronte G; Russo A; Santini D; Perrone F; Tonini G
PLoS One; 2015; 10(7):e0133488. PubMed ID: 26230853
[TBL] [Abstract][Full Text] [Related]
32. Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma.
Oldrini G; Huertas A; Renard-Oldrini S; Taste-George H; Vogin G; Laurent V; Salleron J; Henrot P
PLoS One; 2017; 12(4):e0176118. PubMed ID: 28441447
[TBL] [Abstract][Full Text] [Related]
33. Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma.
Chen Q; Wang J; Wang X; Yin Y; Wang X; Song Z; Xing B; Li Y; Zhang J; Qin J; Jiang R
Clin Lung Cancer; 2024 Jan; 25(1):29-38. PubMed ID: 38008641
[TBL] [Abstract][Full Text] [Related]
34. The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy.
Yu JI; Park HC; Lim DH; Choi Y; Jung SH; Paik SW; Kim SH; Jeong WK; Kim YK
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):814-21. PubMed ID: 24969795
[TBL] [Abstract][Full Text] [Related]
35. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation.
Li H; Guo Z; Si T; Wang H
Eur J Gastroenterol Hepatol; 2013 May; 25(5):620-7. PubMed ID: 23325276
[TBL] [Abstract][Full Text] [Related]
36. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.
Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A
J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821
[TBL] [Abstract][Full Text] [Related]
37. Response stratification and survival analysis of hepatocellular carcinoma patients treated with intra-arterial therapy using MR imaging-based arterial enhancement fraction.
Bonekamp S; Bonekamp D; Geschwind JF; Corona-Villalobos CP; Reyes DK; Pawlik TM; Kamel IR
J Magn Reson Imaging; 2014 Nov; 40(5):1103-11. PubMed ID: 24214827
[TBL] [Abstract][Full Text] [Related]
38. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.
Vernuccio F; Godfrey D; Meyer M; Williamson HV; Salama JK; Niedzwiecki D; Stephens SJ; Ronald J; Palta M; Marin D
AJR Am J Roentgenol; 2019 Dec; 213(6):1232-1239. PubMed ID: 31613663
[No Abstract] [Full Text] [Related]
39. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres.
Keppke AL; Salem R; Reddy D; Huang J; Jin J; Larson AC; Miller FH
AJR Am J Roentgenol; 2007 Mar; 188(3):768-75. PubMed ID: 17312067
[TBL] [Abstract][Full Text] [Related]
40. Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma.
Donati OF; Do RK; Hötker AM; Katz SS; Zheng J; Moskowitz CS; Beattie C; Brown KT
Eur Radiol; 2015 Sep; 25(9):2779-88. PubMed ID: 25850892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
